Kornimate/medical-research-clean huggingface dataset:
tissue collection protocol for gastroesophageal cancers

Conditions: Esophageal Cancer

Summary: this proposed collection of primary tumor cells lines will benefit esophageal cancer research within the university health network. this collection of gastro-esophageal tumor samples will be used to grow primary tumor cell lines, which will provide researchers with ready samples of various gastro-esophageal cancers. this will help to address the issue of access to these cell lines due to the limited number of patients with gastro-esophageal tumors, and high rates of contamination.

samples will be collected during surgery, egd, or other biopsy. the surgeon will resect a sample for the research coordinator and/or fellow who will collect the sample and take it back to the lab for processing. samples collected will be in excess of standard samples that are sent for pathology. the surgeon will make sure that excess samples will not affect pathological diagnosis. in addition samples may be purchased from the national cancer institute's cooperative human tissue network.

Eligibility criteria:
inclusion criteria: * patients with esophagogastric cancer and/or gerd +/- barrett's esophagus who will undergo surgery and/or egd as standard of care. exclusion criteria: * patients who are not well enough to undergo surgery or egd as standard of care.
the study of drotrecogin alfa (activated) in adult patients with severe sepsis at a low risk of death

Conditions: Sepsis

Summary: adult patients with severe sepsis

compared with placebo, drotrecogin alfa (activated) reduces 28-day all-cause mortality in adult patients with severe sepsis at low risk of death (for example, with an acute physiology and chronic health evaluation ii (apache ii) score \<25 or single organ dysfunction).

Eligibility criteria:
inclusion criteria: * adult patients with recent onset of severe sepsis or presence of a suspected or proven infection, and at least one induced organ dysfunction. exclusion criteria: * are indicated for the treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country. * are contraindicated for treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country. * platelet count less than 30,000/mm3.

Keywords: severe sepsis
comparative efficacy of brt and cbt-i for insomnia

Conditions: Insomnia Disorders; Insomnia Disorder; Insomnia; Insomnia Chronic; Insomnia, Primary; Insomnia, Nonorganic; Insomnia Type; Sleep Disorder

Summary: this study evaluates two behavioral treatments for patients with insomnia disorder: bedtime restriction therapy (brt) and cognitive behavioral therapy for insomnia (cbt-i). both therapies aim to improve the clinical symptomatology of insomnia by teaching participants techniques to better manage their sleep schedule and habits. brt is a simpler and shorter therapy focused on aligning the time spent in bed with reported sleep time. cbt-i includes additional components such as relaxation techniques and cognitive exercises. the study will compare these treatments to see if brt is as effective as cbt-i in improving the clinical symptomatology of insomnia.


Eligibility criteria:
inclusion criteria: * must meet dsm-5 criteria for insomnia disorder. * adults aged 18 to 80 years * capable of giving written informed consent. * sufficient fluency in the study site's language (i.e., german or french) to understand all study-related information. exclusion criteria: * unstable, progressive, or degenerative medical condition * acute pain or poorly managed chronic pain * suicidality * uncontrolled psychiatric condition requiring treatment outside of study * alcohol or drug abuse or dependency * diagnosis of psychosis, bipolar disorder, autism, borderline personality disorder, or antisocial personality disorder * clinical evidence of sleep disorders other than insomnia (e.g., sleep apnea, restless legs, periodic limb movements in sleep, parasomnia) * evidence of intellectual disability * regular intake of benzodiazepines (bzd) or benzodiazepine receptor agonists (bzdra) * alteration of medication within 4 weeks prior to study treatment or planned alteration during the trial period (stable medication except bzd or bzdra does not lead to exclusion) * current other psychotherapy for insomnia * known pregnancy or breastfeeding * inability to comply with study procedure * insufficient fluency in german or french to complete the study

Keywords: insomnia cognitive behavioral therapy bedtime restriction sleep restriction
improving patient-centered care for diabetes in bangladesh through "dynamic integration" of vision care on the supply side

Conditions: Diabetes Mellitus; Diabetic Retinopathy (DR)

Summary: the goal of this clinical trial is to review if improved patient-centered diabetes mellitus (dm) care, through the integration of vision services utilizing a patient information system (pis), can promote cooperation between diabetic retinopathy (dr) and dm care providers for participants that are diagnosed with dm and identified with high-risk dr. the main questions it aims to answer are: 1. what proportion of participants' care meets international guidelines upon chart review by a masked clinician observer, compared between study groups. 2. what is the cost-effectiveness, measured as total intervention cost per additional participant complying with the suggested exam, to improve diabetic care. researchers will compare participant adherence with international guidelines when dr results are provided by a pis without specific care recommendations to when the pis provides dr results with specific care recommendations for dm management.


Eligibility criteria:
inclusion criteria: * diagnosed with dm * diagnosed with high-risk dr * over 30 years of age * currently treated at the dinajpur diabetes hospital in bangladesh * willingness to participate in the study exclusion criteria: * other significant causes of vision loss * medical conditions that could impair compliance with follow-up (such as stroke, dementia, etc.) * not willing to participate in the study
effects of acupuncture on aromatase inhibitor-induced joint pain

Conditions: Breast Cancer

Summary: researchers at the john wayne cancer institute (jwci) at providence saint john's health center (psjhc) are trying to examine whether acupuncture reduces joint pain in patients being treated with aromatase inhibitor (ai) therapy for breast cancer and whether the reduction in pain happens by lowering inflammation.

the investigators propose to investigate the effect of acupuncture on patients experiencing joint pain from aromatase inhibitor therapy. the investigators will serially measure patient's symptoms and track current medications, joint pain, daily activities, fatigue, and quality of life. the investigators will collect peripheral blood at baseline, weeks 4 and 7, one week after the last acupuncture treatment and 4 weeks after the last acupuncture treatment. the investigators will study the samples collected at the five predetermined time-points to test for immune parameters, such as the innate and adaptive immune responses, as well as the proliferative capabilities and pro-inflammatory mediators reflected in innate and adaptive functional immune responses.

Eligibility criteria:
inclusion criteria: * female * must be on aromatase inhibitor therapy continuously for breast cancer treatment for at least the preceding two months * must have experienced increased or new onset joint pain daily to a degree equal to or greater than 4 on a pain scale of 0-10 after starting aromatase inhibitor therapy * able to read and write english * able to give written informed consent to participate in the study exclusion criteria: * have a known autoimmune disease or acute infection * have had acupuncture treatment within 6 months of study enrollment * known needle phobia * known metal allergies * have an implantable device, such as pacemaker, defibrillator or other device contraindicated with electrical stimulation * use of nonsteroidal antiinflammatory drugs (nsaids) or narcotics within 7 days of study enrollment and during study period (15 weeks) * receipt of prior chemotherapy, immunotherapy or radiation therapy within 90 days * on anticoagulant therapy * receiving physical or occupational therapy concurrently * taking herbs or herbal teas within 7 days of study enrollment and during study period (15 weeks) * have an immune-compromising medical condition or currently receiving immune-modulating therapies (including corticosteroids) * enrolled in any other active cancer treatment protocols * bone fracture or surgery of an affected extremity within 6 months
long-term outcomes and life satisfaction of adults with pediatric-onset spinal cord injuries

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to assess life satisfaction and long-term outcomes (i.e., medical and psychosocial) of adults who sustained spinal cord injuries (sci) as children or adolescents.

the ultimate goal of rehabilitation for children and adolescents with spinal cord injuries (scis) is to assure that they can grow up to have as productive and satisfying lives as their peers. understanding factors associated with these outcomes of our patients after they have become adults may help to identify interventions and rehabilitation strategies that will optimize long-term outcomes. long-term studies of adults with pediatric-onset sci are needed to identify important outcomes, including survival, participation, health status and health-related quality of life, and life-satisfaction. further, these outcomes need to be compared to population norms. predictive models of important outcomes will be developed using independent factors, including demographic, impairment, functional limitation, participation, and environmental and personal factors. in addition, the impact of age at injury, upper extremity reconstruction or functional electrical stimulation implants, and the mitrofanoff procedure on adult outcomes will be assessed. the stability of selected outcomes in comparison to normative and census data will be determined and factors associated with changes in these outcomes will be assessed.

Eligibility criteria:
inclusion criteria: * individuals who are 19 years of age and older * were injured at the age of 18 years or younger * received care at shriners hospitals for children in chicago, philadelphia, or northern california exclusion criteria: * non-english speaking individuals due to lack of measures in languages other than english and lack of foreign-speaking research assistants * severe brain injury
a 2-stage, phase iii study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus

Conditions: Cutaneous Lupus Erythematosus

Summary: this study aims to evaluate the efficacy and safety of subcutaneous (sc) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (cle).

the primary objectives of the study are to evaluate the efficacy of anifrolumab compared with placebo in reducing skin disease in participants with active chronic and/or subacute cle who are refractory and/or intolerant to antimalarial therapy. the secondary objectives of the study are to evaluate additional efficacy parameters of anifrolumab, safety, tolerability, quality of life, pharmacokinetics, pharmacodynamics, and immunogenicity. stage 1 and stage 2 of the study will have broadly identical study designs with the exception of sample size. both stages of the study will have a randomized, double-blind, placebo-controlled design, followed by an open-label treatment period.

Eligibility criteria:
key inclusion criteria: * participants must have a confirmed diagnosis of cle. diagnosis must be clinically and histologically confirmed with the following: * clasi-a total score ≥ 10 points at screening and confirmed at randomization. * cla-iga-r erythema score of ≥ 3 and cla-iga-r-omc score of ≥ 1 at screening and confirmed at randomization. * inadequate response or intolerant to antimalarial therapy. * participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (tb) and the same should reflect in chest radiograph or a chest ct scan result. * contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * participants should have a coronavirus disease 2019 (covid-19) negative pcr or antigen test result as per local policies at screening. key exclusion criteria: * history or evidence of suicidal ideation. * severe or life-threatening systemic lupus erythematosus (sle). * active sle or sjögren's syndrome. * any active skin conditions other than cle that may interfere with the study. * history of recurrent infection requiring hospitalization and iv antibiotics. * covid-19 infection * any history of an anaphylactic reaction to human proteins, or monoclonal antibodies. * at screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc. note: other protocol defined inclusion/exclusion criteria may apply

Keywords: lupus erythematosus cutaneous lupus erythematosus anifrolumab cutaneous lupus erythematosus disease area severity index cutaneous lupus activity - investigator's global assessment - revised
diameters and wall-to-lumen ratio of retinal arterioles in patients with retinal vein occlusion.

Conditions: Hypertensive Patients With Retinal Vein Occlusion

Summary: to evaluate the wall-to-lumen ratio (wlr) of retinal arterioles in hypertensive patients with retinal vein occlusion (rvo) before and after dexamethasone intravitreal implant 0.7 mg (dex) compared to a matched control group of normal eyes in non-hypertensive subjects.


Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study; * age \> 20 years; * decreased visual acuity as a result of clinically detectable me associated with either crvo or brvo; * the duration of macular edema was required to be between 4 and 24 weeks for both crvo and brvo; * retinal thickness in the central subfield (as measured using optical coherence tomography) had to be \> 350 µm in the study eye. exclusion criteria: * the exclusion criteria were as follows: diabetes; previous intravitreal anti-vegf therapy or intravitreal steroid therapy; previous photodynamic therapy or focal laser; active retinal or optic disc neovascularization; active or history of choroidal neovascularization; presence of rubeosis iridis; any active infection; glaucoma, current ocular hypertension, or a history of steroid-induced intraocular pressure (iop) increase in either eye; or concurrent eye disease in the study eye that could compromise visual acuity (e.g., choroidal neovascularization, diabetic retinopathy, epiretinal membrane).

Keywords: retinal vein occlusion systemic hypertension arteriolar diameter
metabolic activation of brain areas with emotional stimuli compared with score in psychological test

Conditions: Emotional Disorder

Summary: quantitative assessment of the activation of brain areas by functional magnetic resonance imaging (frmi) in the face of positive and negative emotional stimuli using audiovisual materials validated for the local population and its correlation with degrees of emotional disorder based on a score obtained by a validated questionnaire for the local population, in 16 volunteers from the city of la rioja in argentina.

the technology applied in fmri allows us to visualize on a color scale the changes in blood flow in those sectors of the brain that increase their metabolic activity during a given action. this is achieved by mapping the cerebral blood volume, which increases or decreases according to the metabolic activity in a certain region of the brain. this indirect method of measuring the metabolic activity of brain areas is very useful for anatomically identifying motor areas and critical functions in individual patients prior to neurosurgery, to allow better surgical planning. currently this is its main application in healthcare practice. in the field of research it is applied in clinical neurology, psychiatry and psychology. studies have been conducted on the activations of brain regions in basic emotions. there is less data on the quantitative differences of these activations in the argentine population according to the degree of emotional disorder, this being the object of study of this project. emotional disorders are transversal to different pathologies, with or without a psychotic component.

Eligibility criteria:
inclusion criteria: - must be able to understand the instructions and collaborate during the data adquisition. exclusion criteria: * any contraindication to enter an mri (for example, a pacemaker) * claustrophobia.

Keywords: fmri emotion cerebral blood volume
24-hour intraocular pressure control with bimatoprost/timolol versus latanoprost as first choice

Conditions: Glaucoma

Summary: the primary objective of this crossover 24-hour intraocular pressure (iop) trial is to compare the control obtained after 3 months of therapy with the bimatoprost/timolol fixed combination (btfc, ganfort) given once in the evening (20:00) versus latanoprost (xalatan) administered once in the evening (20:00) in newly-diagnosed patients with exfoliation syndrome (xfs) and ocular hypertension, or exfoliative glaucoma (xfg) previously untreated and iop greater than 29 mm hg.


Eligibility criteria:
inclusion criteria: * patient has exfoliation syndrome with ocular hypertension, or exfoliative glaucoma and is older than 29 years * patient is newly diagnosed, or currently untreated and exhibits untreated morning iop (2 separate iop readings at 10:00)greater than 29 mm hg in the study eye * study patients should have mild to moderate exfoliative glaucoma (vf loss \<12 db; cupping 0.8 or less) * patient with exfoliation syndrome should fulfill the iop criterion (iop \> 29 mm hg at 10:00) * patient deemed by investigator to require significant iop reduction to obtain desired target iop * patient agrees to be treated for at least 3 months with latanoprost and bimatoprost/timolol fixed combination drops dosed in the evening * in study eye distance best corrected snelen visual acuity greater than 1/10 exclusion criteria: * contraindications to therapy with latanoprost, bimatoprost, or β-blockers * history of non-adherence or previously recorded evidence of lack of response (\<10% morning iop reduction) to any antiglaucoma medication * patient can not understand the instructions and adhere to medications * patient is a female of childbearing potential or lactating mother * past history of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses * signs of ocular infection, except blepharitis, or corneal abnormality that may affect iop measurements * the other eye can not receive the same therapy, or remain without medical therapy * closed angles
an observational study of patients living with chronic neurological diseases

Conditions: Neurological Diseases or Conditions; Dementia of Alzheimer Type; Alzheimer Disease; Mild Cognitive Impairment; Parkinson Disease; Multiple Sclerosis

Summary: target-neuro is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: alzheimer's disease and related dementia (adrd), mild cognitive impairment (mci), parkinson's disease (pd), and multiple sclerosis (ms).


Eligibility criteria:
disease cohort inclusion criteria: •adult patients at the time of enrollment with a diagnosis of adrd, mci, pd, or ms by select icd-10 codes in the ehr interface exclusion criteria: * death * manual removal (sponsor or site request) * no ehr interface encounter \> 3 years engaged cohort inclusion criteria: * adult patients diagnosed and managed for these conditions invited to participate * ability to provide written informed consent (or have a legally authorized representative to provide informed consent) * care partners may be invited to participate in surveys and will provide informed consent. exclusion criteria: * patient expressed desire to withdraw consent to complete pros * care partner expressed desire to withdraw consent to complete pros * failure to complete pros within 24 weeks of initial invitation * greater than 24 months lapse of survey completion after baseline surveys completed * additionally, the criteria detailed for disease cohort apply to the engaged cohort age cohort inclusion criteria: •adult patients aged 60 and older at time of enrollment exclusion criteria: * death * manual removal (sponsor or site request) * no ehr interface encounter \> 3 years
morphological pattern of the atrophic posterior maxillae

Conditions: Bone Deficiency, Posterior Maxillae

Summary: overcoming the vertical and horizontal bone deficiency in the posterior maxillae are considered as the most challenging scenarios for implant-supported oral rehabilitation in modern implant dentistry. therefore, a comprehensive and precise understanding of such anatomical structures are needed to avoid potential complications that ultimately might jeopardize the treatment outcome. cone-beam computerized tomography (cbct) offers some advantages to conventional ct-scan such as lower-dose radiation with high isotropic spatial resolution and cost. therefore, it offers a viable and reliable tool to study anatomical structures such as the posterior atrophic maxillae


Eligibility criteria:
* images were included if: 1. pristine maxillary posterior atrophic ridges (between premolars and molars) as a result of missing single or multiple teeth for over than 12 months. 2. residual ridge height (rh) was \< 10 mm. 3. presence of teeth adjacent to or opposing the edentulous area so the location of the edentulous ridges corresponding to the tooth site could be identified. 4. the maxillary sinus to be measured was visible from its floor to at least 15 mm from the alveolar crest of the edentulous ridge. * images were excluded if: 1. images were unclear or incomplete due to scattering or other reasons 2. edentulous ridge height was more than 10 mm 3. ridge preservation/augmentation simultaneous/delayed to tooth extractions 4. grafted maxillary sinus for implant-supported prosthesis 5. the location of the edentulous ridge cannot be determined 6. implants or other prosthetic device restoring the posterior ridge 7. presence of sinus pathology that made the measurement impossible 8. the outline of the edentulous ridge cannot be identified due to low 'grey scale' density

Keywords: bone maxilla cone-beam computed tomography regeneration